Fact sheet

Sub-population Optimization and Modeling Solution

A new approach to find hidden opportunities in failed trials

The challenge

With the cost to bring a therapy to market continuously increasing, failed trials can cost sponsors upwards of a billion dollars. Failed trials often have hidden sub-populations of patients who respond well to the treatment being evaluated; however, the trial is abandoned because of the overall data. This results in a financial loss for sponsors and missed opportunities for patients to benefit from a therapeutic innovation. Traditionally, the only way to analyze potentially promising results in sub-populations is a resource-intensive, manual biostatistics process that can take up to 6 months.



The solution

Biomarker-driven sub-population optimization in clinical trials

IQVIA's Sub-population Optimization and Modeling Solution (SOMS) leverages the latest healthcare-grade AI technology available and can help you identify predictive biomarkers and promising subgroups for your clinical trials. SOMS can achieve rapid outputs in as little as 30 seconds — up to a 99% time savings over your current biostatistics process — delivered in easy-to-read charts, scatter plots and summaries. This streamlined, data-driven and reproducible approach can be leveraged across all studies. In turn, biostatistician resources are freed up for key strategic activities instead of manual tasks.

The analysis is based on an industry method, Subgroup Identification Based on Differential Effect Search (SIDES), that is validated, published and defendable to health authorities. Utilizing secure data technologies and streamlined workflows, SOMS enables sponsors to:

- Identify predictive biomarkers and sub-populations
- Track sub-populations
- Design and adjust strategies to maximize trial success
- Develop rescue strategies for poor performing trials
- Execute trial simulation and benchmarking

A biomarker-driven approach to identifying sub-populations

Proven technology backed by IQVIA, compliant with regulatory standards



Technology: SaaS technology licensing per study

Services: IQVIA biostatistician end-to-end execution and analysis or à la carte

Evolution to a streamlined, data-driven and repeatable process

Shortening your current process from months to hours

SOMS process | 26-40 hours



Interested in IQVIA SOMS? Join our pilot program.

IQVIA is currently recruiting industry sponsors who are ready to reap the benefits of IQVIA SOMS. Based on the need for your trial we can design, track, or classify sub-populations to generate insights for your team. Minimum effort is required from your end, and you can retain access to the software at a discount, past the pilot phase.

If you are interested in joining our SOMS pilot program, reach out to schedule a consultation.

IQVIA TECHNOLOGIES

CONTACT US

OrchestrateYourTrials@iqvia.com

iqvia.com/CDAS